Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can scheduled malaria drugs shield infants from severe illness?

NCT ID NCT05856357

Prevention Sponsor: London School of Hygiene and Tropical Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This trial tests whether giving infants in Côte d'Ivoire a preventive dose of an antimalarial drug at routine health visits can lower their risk of malaria and anemia. Researchers will compare outcomes for infants in areas receiving this intervention against those receiving standard care. The study follows infants for 18 months, tracking malaria cases, anemia, and deaths to see if this strategy offers meaningful protection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sulfadoxine-pyrimethamine, an antimalarial drug given to infants as preventive treatment
What this could lead to
If effective, this approach could reduce malaria cases, severe anemia, and deaths in infants, offering a practical prevention strategy for malaria-endemic regions.
What could go wrong
The trial is still in progress, and results may not show a clear benefit. There are also risks of drug resistance and side effects in infants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,381 people

The number who actually took part.

Started

Aug 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Children up to 6 months of age in Seguela and Kani health districts of Côte d'Ivoire.

Ages

Up to 6 months

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Reside in Seguela (intervention) or Kani (control) health districts. * Agree to take part in the census. * Aged 10 weeks to six months at the time of enrolment. * Parent/caregiver informed consent obtained. Exclusion Criteria: * Parent/caregiver refused to participate in the cohort. * Parent/caregiver did not give informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia Malaria

Contacts and locations

Locations

  • Multiple

    Séguéla, Côte d’Ivoire

More trials for these conditions

Other studies related to the condition(s) this trial covers.